TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03515837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline solution
Description: IV infusion
Study: NCT00810615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen @ 2.4 ATA
Description: Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Study: NCT03967106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischaemic Preconditioning
Description: IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
Study: NCT00977262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat shake
Description: milkshake containing 95 gram of fat, high percentage polyunsaturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat shake
Description: milkshake containing 95 gram of fat, high percentage polyunsaturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat shake
Description: milkshake containing 95 gram of fat, high percentage polyunsaturated fat
Study: NCT03357601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCEET
Description: The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
Study: NCT03967106

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
Study: NCT04537936

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaning Centered Psychotherapy for Latinos
Description: MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy for Latinos
Description: MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
Description: Determines the degree of spiritual well-being

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
Description: Determines the degree of spiritual well-being

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
Description: Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
Description: Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-assessment questionnaire
Description: Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-assessment questionnaire
Description: Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
Study: NCT00996632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
Description: mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional diarthermy knife
Description: mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
Study: NCT02396069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-289
Description: PARP-1 inhibitor
Study: NCT02607579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Study: NCT02396069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00142844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study: NCT02607579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT03806738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention-specific Carevive questionnaire
Description: includes standard of care questions with additional decision-making questions

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care questionnaire
Description: includes the standard of care questions that are already in place for Carevive questionnaires
Study: NCT03540927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM+ for entrepreneurs
Description: The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cash transfer to the Entrepreneurs
Description: The entrepreneurs in the control arm will receive cash transfer only for their businesses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer to the Entrepreneurs
Description: The entrepreneurs in the control arm will receive cash transfer only for their businesses.
Study: NCT03655158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ozone device ( Ozonytron XL )
Description: The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
Study: NCT00142844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01185730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Heart Catheterization
Description: all patients of the all centers will have Right Heart Catheterization at the diagnosis
Study: NCT00203957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
Study: NCT02079428

Intervention type: OTHER
Intervention: No interventions
Study: NCT03959137

Intervention type: OTHER
Intervention: None - Common practice
Description: None - Common practice
Study: NCT04737811

Intervention type: OTHER
Intervention: Turkish Version of Swallowing Disturbance Questionnaire
Description: The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
Study: NCT06110221

Intervention type: OTHER
Intervention: Periodontal clinical measurements, GCF and saliva sampling
Description: Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis.

Intervention type: OTHER
Intervention: Periodontal clinical measurements, GCF and saliva sampling
Description: Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis.

Intervention type: OTHER
Intervention: Periodontal clinical measurements, GCF and saliva sampling
Description: Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis.
Study: NCT00196573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder bursectomy alone
Study: NCT02711579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02231307

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUBLIVAC FIX Birch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBLIVAC FIX Birch
Study: NCT00991042

Intervention type: OTHER
Group type: OTHER
Intervention: blood collect
Description: Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
Study: NCT02956005

Intervention type: DRUG
Group type: OTHER
Intervention: ENVARSUS®
Description: ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
Study: NCT00561184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Description: One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Description: One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
Study: NCT04673266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.
Study: NCT02179762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Logs
Description: The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Logs
Description: The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence
Description: We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
Study: NCT01958593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy before and after experimental sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy before and after experimental sessions.
Study: NCT04089163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC (extended-release formulation of flucytosine)
Description: Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
Study: NCT02103634

Intervention type: DEVICE
Intervention: NaF PET/MRI

Intervention type: DEVICE
Intervention: NaF PET/CT
Description: NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.

Intervention type: DEVICE
Intervention: FDG PET/CT
Study: NCT05371418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical (guided tissue regeneration)
Description: In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic intrusion followed by guided tissue regeneration GTR
Description: . In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
Study: NCT02394431

Intervention type: OTHER
Intervention: Cardiac echography
Description: Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.

Intervention type: OTHER
Intervention: Cardiac echography
Description: Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.

Intervention type: OTHER
Intervention: Biological parameters
Description: Hemoglobin levels, red cells, hematocrit, iron, ferritin

Intervention type: OTHER
Intervention: Biological parameters
Description: Hemoglobin levels, red cells, hematocrit, iron, ferritin

Intervention type: OTHER
Intervention: Clinical parameters
Description: Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
Study: NCT01096407

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Collection of urine samples

Intervention type: OTHER
Intervention: questionnaire administration
Description: Completion of questionnaires

Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: An assessment will be completed.
Study: NCT01412710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
Study: NCT02300818

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field Therapy
Description: Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seawater eyedrops
Description: Eye-drops daily 1 time a day for 12 weeks
Study: NCT01447316

Intervention type: OTHER
Intervention: Subject outcomes following bariatric surgery
Description: Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
Study: NCT01457729

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivation by Telephone Call
Description: Telephone call not exceeding 10 minutes according to a protocol
Study: NCT02428231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Participants will be dosed twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate
Description: Participants will be dosed twice daily for 12 weeks.
Study: NCT03157310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Daily oral administration of 250 mg Gefitinib
Study: NCT02179762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence
Description: We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence
Description: We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and body composition test
Description: Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and body composition test
Description: Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and body composition test
Description: Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
Study: NCT04527692

Intervention type: OTHER
Intervention: Questionnaire
Description: semi-structured interviews on the quality of life

Intervention type: OTHER
Intervention: Questionnaire
Description: semi-structured interviews on the quality of life
Study: NCT04012021

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7T Magnetic Resonance Imaging
Description: * T1-weighted and T2-weighted sequences~* quantitative magnetic resonance imaging approach~* proton spectrum analyses
Study: NCT02929771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung GearVR
Description: VR with head mounted display (HMD) and headphones. Treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad
Description: iPad with headphones. Control
Study: NCT03458117

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec (T-VEC)
Description: a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)